The drug, which has US sales of $136 million, gets 180-day marketing exclusivity
Hyderabad-based drug firm Dr Reddy’s Laboratories Limited (DRL) has launched Finasteride Tablets (1 mg), a bio-equivalent generic version of Propecia (Finasteride) tablets in the US market on January 02.
Dr Reddy’s abbreviated new drug application (ANDA) for Finasteride 1 mg tablets has been awarded a 180-day period of marketing exclusivity in the US on 2 Jan, 2013, the company said in a filing to the Bombay Stock Exchange (BSE) .
The Propecia tablets brand has US sales of approximately $136 million medication assisted treatment (MAT) for the most recent twelve months ending in October 2012 according to IMS Health, the filing said.
Dr Reddy’s Finasteride Tablets 1 mg is available in bottle counts of 30 and 90.
The company's scrip is currently trading at Rs 1,884.60 on the BSE, up 2.55 per cent over the previous day's close of Rs 1,837.80.
After they together paid Rs 12 lakh to settle charges related to alleged delay in amending insider trading norms